Archives
-
L-Phenylephrine in α1A Receptor Research
2026-09-01
L-Phenylephrine is an adrenergic α1A receptor agonist used to study α1-adrenergic receptor signaling, vasoconstriction, cardiomyocyte stress responses, and neural progenitor biology. Product evidence and a peer-reviewed mouse study support its value as a mechanistic research tool, but they do not establish a therapeutic use for sex-specific hypertension.
-
ML216: BLM Helicase Inhibition in Cancer Assays
2026-09-01
ML216 is a BLM helicase inhibitor for dissecting DNA repair dependencies, replication stress, and tumor cell sensitization to chemotherapy. This article explains how to distinguish BLM-specific activity from broader RecQ helicase effects and translate biochemical, cellular, and xenograft findings into rigorous assay decisions.
-
Human PSC Teratomas Reveal Skeletal Myogenic Lineage
2026-08-31
Pappas and colleagues show that human pluripotent stem cell-derived teratomas generate skeletal myogenic progenitors spanning developmental stages that resemble embryonic human myogenesis. Single-cell transcriptomics and surface-marker analysis identify ERBB3 and CD82 as useful candidates for prospective isolation, establishing teratomas as an accessible platform for studying and obtaining human muscle progenitors.
-
LLY-507: Selective SMYD2 Inhibitor Workflows
2026-08-31
LLY-507 combines sub-15 nM biochemical potency with strong target selectivity, making it useful for connecting SMYD2 methyltransferase activity to cancer-cell phenotypes. This guide translates the compound into practical methylation, proliferation, apoptosis, and renal-fibrosis assay workflows while emphasizing controls and interpretation limits.
-
GS967 for Cardiac Late Sodium Current Studies
2026-08-30
GS967 is a cardiac late sodium current inhibitor designed to separate pathological late Na⁺ influx from broader conduction effects. Its concentration-dependent activity supports workflows spanning in vitro cardiac electrophysiology, ventricular myocyte sodium current inhibition, and ex vivo arrhythmia prevention research.
-
LLY-507: Reading SMYD2 Biology Across Models
2026-08-29
LLY-507 is a selective SMYD2 inhibitor for dissecting methyltransferase-dependent signaling in cancer and tissue injury. This article presents a model-to-assay framework that separates biochemical potency, cellular target engagement, phenotype, and translational evidence.
-
Mtb–BMX Signaling Rewires Lysosomal Acidification
2026-08-28
The reference study identifies a host–pathogen mechanism in which M. tuberculosis Chp2/Rv1184 promotes BMX-dependent phosphorylation of ATP6V1E1, disrupting V-ATPase assembly and lysosomal acidification. The findings connect a secreted mycobacterial protein to a specific host kinase pathway and support further evaluation of BMX and lysosomal acidification as host-directed tuberculosis targets.
-
Tetracycline Workflows for Selection and Ribosome Studies
2026-08-28
Tetracycline supports more than routine antimicrobial selection: it enables controlled bacterial protein-synthesis studies, plasmid workflow quality control, and ribosomal function research. This guide connects practical reagent handling with assay-design lessons from a lung adenocarcinoma study while clearly separating validated findings from optimization recommendations.
-
Prednisolone Workflows for Glucocorticoid Research
2026-08-27
Build reproducible Prednisolone assays for glucocorticoid receptor signaling, inflammation modulation, and immunology research. A practical comparison with ERAD-engaging degradation highlights how to use this synthetic glucocorticoid as a pathway perturbagen without confusing it with a membrane-protein degrader.
-
GI 254023X: ADAM10 Inhibitor Workflows
2026-08-27
GI 254023X combines strong ADAM10 inhibition with more than 100-fold selectivity over ADAM17, enabling focused studies of sheddase activity, Notch1 signaling, and endothelial barrier failure. This practical guide translates its biochemical profile into cell-based workflows, orthogonal readouts, and troubleshooting strategies for vascular and immunological research.
-
SM-102: Practical LNP Workflow for mRNA Delivery
2026-08-26
Learn how to handle SM-102, assemble lipid nanoparticles, and build a reproducible mRNA delivery workflow around controlled formulation screens. The guide combines product-specific handling with machine-learning-informed comparison, emphasizing why N/P ratio, mixing, and analytical quality control must be interpreted together.
-
From S-Phase Signal to Translational Confidence
2026-08-26
A mechanistic and strategic guide to using EdU Imaging Kits (Cy3) to connect senescence-related cancer signatures with functional proliferation data, especially in cholangiocarcinoma research.
-
Ibotenic Acid: NMDA Receptor Agonist Workflows
2026-08-25
Ibotenic acid is a research-use-only NMDA receptor agonist for controlled studies of glutamatergic signaling, neuronal activation, and lesion-associated phenotypes. This guide translates product handling and recent dose–time toxicity findings into practical workflows, assay choices, and troubleshooting checkpoints for reproducible neuroscience research.
-
nor-Binaltorphimine dihydrochloride: Causal KOR Assays
2026-08-25
Explore how nor-Binaltorphimine dihydrochloride can convert a brain-to-spinal circuit discovery into a causal opioid receptor signaling assay. This guide emphasizes laterality, temporal dynamics, controls, formulation, and interpretation rather than repeating a generic antagonist workflow.
-
Nano-Granulated Zoledronate Reprograms Innate Immunity
2026-08-24
Chen et al. develop nano-granulated zoledronate (Nano-ZD) to redirect mevalonate-pathway modulation toward innate immune cells in draining lymph nodes. The study links CoQ depletion to altered oxidative phosphorylation and pyrimidine metabolism, showing that Nano-ZD can strengthen vaccine-induced and antitumor immunity, particularly when combined with MPLA and αPD-L1.